NAMS newamsterdampharma.com Net earnings per share for the last 12 months

Public company logo of NewAmsterdam Pharma (NAMS)

NewAmsterdam Pharma revenues are based on the market launch of the innovative Obicetrapib for cholesterol management. This 12-month net income per share chart visualizes this trajectory, where the value of -1.71 reflects this status. The company's strategy relies on creating an affordable oral alternative to injections. Minimal geopolitical influence on the biopharmaceutical sector supports the business's stability.

NAMS (NewAmsterdam Pharma Corp) Net earnings per share (EPS TTM) history from 06/21/2023 to 11/17/2026

Analytical breakdowns and data insights for company NewAmsterdam Pharma Corp (NAMS)

Fundamental company valuation:NewAmsterdam Pharma Company (NAMS)
Mass-produced product of NewAmsterdam Pharma N.V.

This indicator determines the equity value of the asset by calculating the aggregate net income over four quarters per ordinary share. The annual net income per share trend reflects capital management efficiency, while the current negative trend for NewAmsterdam Pharma (NAMS) is driven by development costs for a cholesterol drug, which is standard prior to the commercialization stage.

Competitors of NewAmsterdam Pharma

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months soleno.life SLNO|Amicus Corp (FOLD) - Net earnings per one share for the last twelve months|ETNB - Earnings per share for the last twelve months|AGIO: Earnings per share for the last twelve months|GPCR: Net earnings per share (EPS TTM)|MDXG - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Rezolute Bio|Lexicon Corp (LXRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months mbxbio.com (MBX)|Net earnings per share (EPS TTM) altimmune.com (ALT)|Net earnings per share (EPS TTM) AARD (aardvarktherapeutics.com)|Net earnings per share for the last four quarters Sagimet Biosciences Inc. (SGMT)|BioAge Labs, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Biomea Fusion Corp BMEA|QNCX: Net earnings per share (EPS TTM)|Fractyl Health, Inc. (GUTS) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months VTVT|Agape ATP Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PLUR|SYBX - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) LPCN (lipocine.com)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS